Adipokine effects on bone

Clinical Reviews in Bone and Mineral Metabolism

Volumn 7, Issue 3, 2009, Pages 240-248

  Reid, Ian R ^a   Richards, J B ^b,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MCGILL UNIVERSITY   (Canada)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Adiponectin; Fat; Insulin; Lean; Leptin; Resistin

Indexed keywords

EID: 77956872301     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-009-9048-4     Document Type: Article

References (72)

1. Riis BJ, Rodbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int. 1986;38:318-22. (Pubitemid 16081448)
2. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45-51.
3. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197-207. (Pubitemid 30064908)
4. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke HZ, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73-8.
5. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175:405-15. (Pubitemid 35414387)
6. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630-8. (Pubitemid 29149231)
7. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85:825-36. (Pubitemid 34462792)
8. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16:1426-33. (Pubitemid 32675194)
9. Iwaniec UT, Shearon CC, Heaney RP, Cullen DM, Yee JA. Leptin increases number of bone nodules in vitro. Bone. 1998;23(5 suppl):S212.
10. Maor G, Rochwerger M, Segev Y, Phillip M. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res. 2002;17:1034-43. (Pubitemid 34535141)
11. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17:200-9. (Pubitemid 34087652)
12. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology. 2001;142:3546-53. (Pubitemid 32681763)
13. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang XL, Liu XY, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514-20. (Pubitemid 40477060)
14. Takeda S, Elefteriou F, Levasseur R, Liu XY, Zhao LP, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305-17. (Pubitemid 35345151)
15. Morroni M, De Matteis R, Palumbo C, Ferretti M, Villa I, Rubinacci A, et al. In vivo leptin expression in cartilage and bone cells of growing rats and adult humans. J Anat. 2004;205:291-6. (Pubitemid 39406156)
16. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546-9.
17. Iwaniec UT, Boghossian S, Dube MG, Torto R, Arzaga RR, Wronski TJ, et al. Effects of central leptin gene therapy on weight reduction and cancellous bone mass in female rats. J Bone Mineral Res. 2005;20(suppl 1):s13-4.
18. Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides. 2005;26:2559-66. (Pubitemid 41676732)
19. Hamrick MW, Ding K, Ponnala S, Ferrari SL, Isales CM. Caloric restriction decreases cortical bone mass but spares trabecular bone in the mouse skeleton: implications for the regulation of bone mass by body weight. J Bone Miner Res. 2008;23:870-8. (Pubitemid 351768805)
20. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, et al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Mineral Res. 2005;20:613-8. (Pubitemid 40393069)
21. Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90:5212-6. (Pubitemid 41262276)
22. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004;34:376-83. (Pubitemid 38314902)
23. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Mineral Res. 2005;20:994-1001. (Pubitemid 40712824)
24. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA. 2004;101:3258-63. (Pubitemid 38327768)
25. Martin A, David V, Malaval L, Lafage-Proust M, Vico L, Thomas T. Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology. 2007;148:3419-25. (Pubitemid 46997001)
26. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879-84. (Pubitemid 29427050)
27. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-97. (Pubitemid 39166262)
28. Prouteau S, Berthamou L, Courteix D. Relationships between serum leptin and bone markers during stable weight, weight reduction and weight regain in male and female judoists. Eur J Endocrinol. 2006;154:389-95.
29. Bajoria R, Sooranna SR, Chatterjee R. Leptin and bone turnover in monochorionic twins complicated by twin-twin transfusion syndrome. Osteoporos Int. 2007;18:193-200. (Pubitemid 46090223)
30. Roux C, Arabi A, Porcher R, Garnero P. Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone. 2003;33:847-52. (Pubitemid 37393496)
31. Weiss LA, Barrett-Connor E, von Muhlen D, Clark P. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo study. J Bone Mineral Res. 2006;21:758-64.
32. Nakano Y, Tobe T, ChoiMiura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120:803-12. (Pubitemid 26385421)
33. Wang Y, Lam KSL, Chan L, Chan KW, Lam JBB, Lam MC, et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem. 2006;281:16391-400.
34. Suzuki S, Wilson-Kubalek EM, Wert D, Tsao TS, Lee DH. The oligomeric structure of high molecular weight adiponectin. FEBS Lett. 2007;581:809-14. (Pubitemid 46282708)
35. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83. (Pubitemid 29299050)
36. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord. 2008;6:87-102. (Pubitemid 351769254)
37. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30. (Pubitemid 46498041)
38. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab. 2008;93:3165-72.
39. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obesity. 2008;32:772-9. (Pubitemid 351670618)
40. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Rumley A, Brown K, et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obesity. 2007;31:1089-98. (Pubitemid 46987759)
41. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-9. (Pubitemid 36091630)
42. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29:1357-62. (Pubitemid 44125935)
43. Hoffstedt J, Arvidsson E, Sjolin E, Wahlen K, Arner P. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab. 2004;89:1391-6. (Pubitemid 38368442)
44. Peake PW, Kriketos AD, Campbell LV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Euro J Endocrinol. 2005;153:409-17. (Pubitemid 41410498)
45. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care. 2002;25:1665-6.
46. Lindstrom T, Frystyk J, Hedman CA, Flyvbjerg A, Arnqvist HJ. Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration. Clin Endocrinol. 2006;65:776-82. (Pubitemid 44772359)
47. Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol. 2007;157:481-9. (Pubitemid 350018452)
48. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Parving HH, et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab. 2008;93:3186-91.
49. Modan-Moses D, Stein D, Pariente C, Yaroslavsky A, Ram A, Faigin M, et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab. 2007;92:1843-7. (Pubitemid 46997198)
50. Dostalova I, Smitka K, Papezova H, Kvasnickova H, Nedvidkova J. Increased insulin sensitivity in patients with anorexia nervosa: the role of adipocytokines. Physiol Res. 2007;56:587-94.
51. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 2006;99:196-208. (Pubitemid 44297964)
52. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842-9. (Pubitemid 39349215)
53. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520-6. (Pubitemid 40602668)
54. Yamaguchi N, Kukita T, Li YJ, Argueta JGM, Saito T, Hanazawa S, et al. Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol. 2007;49:28-34. (Pubitemid 46160583)
55. Nampei A, Hashimoto J, Maeda K, Ono T, Nakamur N, Ando W, et al. Adiponectin deficiency partially protects against age-related trabecular bone loss in male mice. J Bone Miner Res. 2004;19:S132.
56. Williams GA, Wang Y, Callon KE, Watson M, Lin J, Lam JBB, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology. 2009 (in press).
57. Jurimae J, Rembel K, Jurimae T, Rehand M. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res. 2005;37:297-302. (Pubitemid 40896213)
58. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646-51. (Pubitemid 37222391)
59. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92:1517-23. (Pubitemid 46556433)
60. Cornish J, Callon KE, Lin J-M, Reid IR. Resistin, an adipocytokine, stimulates osteoblast and osteoclast proliferation. Bone. 2006;38(suppl 1):s9.
61. Thommesein L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006;99:824-34. (Pubitemid 44522000)
62. Dagogojack S, Alali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab. 1997;82:2821-5. (Pubitemid 27385631)
63. Wetvik J. Radiological features in generalized lipodystrophy. Acta Paediatr. 1996;413:44-51.
64. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int. 2006;17:495-500.
65. Reid IR, Evans MC, Cooper GJS, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993;265:E655-9.
66. Stolk RP, Vandaele PLA, Pols HAP, Burger H, Hofman A, Birkenhager JC, et al. Hyperinsulinemia and bone mineral density in an elderly population - the Rotterdam study. Bone. 1996;18:545-9. (Pubitemid 26257875)
67. Haffner SM, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metab Clin Exp. 1993;42:735-8. (Pubitemid 23173413)
68. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabetes Med. 2000;17:124-9. (Pubitemid 30159047)
69. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RMJ. Features of the metabolic syndrome and the risk of nonvertebral fractures: the Tromso study. Osteoporos Int. 2006;17:426-32.
70. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305-10. (Pubitemid 46556402)
71. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996;50:1087-94. (Pubitemid 26384846)
72. Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science. 2004;303:229-32. (Pubitemid 38057572)